Drug Approval | September 21, 2021
U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
